BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM. Currently, B-cell maturation antigen (BCMA) has emerged as the most comm...

Full description

Saved in:
Bibliographic Details
Published inHaematologica Vol. 108; no. 4; pp. 958 - 968
Main Authors Zhou, Xiang, Rasche, Leo, Kortüm, K Martin, Mersi, Julia, Einsele, Hermann
Format Journal Article Book Review
LanguageEnglish
Published Italy Fondazione Ferrata Storti 01.04.2023
Ferrata Storti Foundation
Subjects
Antibodies, Bispecific - therapeutic use
B-Cell Maturation Antigen
Biology
Humans
Immunotherapy
Immunotherapy, Adoptive - adverse effects
Multiple Myeloma - drug therapy
Neoplasm Recurrence, Local - drug therapy
Receptors, Chimeric Antigen
Review
Online AccessGet full text

Cover

More Information
Summary:The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric antigen receptor modified T cells and bispecific antibodies are bringing new treatment options to patients with relapsed/refractory MM. Currently, B-cell maturation antigen (BCMA) has emerged as the most commonly used target of T-cell-based immunotherapies for relapsed/refractory MM. Clinical data have demonstrated promising efficacy and manageable safety profiles of both chimeric antigen receptor T-cell and bispecific antibody therapies in heavily pretreated relapsed/refractory MM. However, most patients suffer from relapses at later time points, and the mechanism of resistance remains largely unknown. Theoretically, loss of antigen is a potential tumor-intrinsic resistance mechanism against BCMA-targeted immunotherapies. Strategies to overcome this kind of drug resistance are, therefore, needed. In this review, we discuss the loss of BCMA in the new epoch of immunotherapy for MM.
Bibliography:content type line 1
SourceType-Scholarly Journals-1
ObjectType-Review-1
Disclosures
Contributions
XZ, LR, and KMK performed the literature research, analyzed and interpreted the data, and drafted the work; JM and HE conceived the design of the work and substantially revised it. All the authors approved the submitted version.
No conflicts of interest to disclose.
ISSN:0390-6078
1592-8721
DOI:10.3324/haematol.2020.266841